Patents by Inventor James N. Chang

James N. Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190070252
    Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.
    Type: Application
    Filed: March 27, 2018
    Publication date: March 7, 2019
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Publication number: 20180078606
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: May 3, 2017
    Publication date: March 22, 2018
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20170216414
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 9622957
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: April 18, 2017
    Assignee: Allergan, Inc.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Publication number: 20160354384
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: May 5, 2016
    Publication date: December 8, 2016
    Inventors: CHIN-MING CHANG, JAMES N. CHANG, RHETT M. SCHIFFMAN, R. SCOTT JORDAN, JOAN-EN CHANG-LIN
  • Publication number: 20160250225
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: October 6, 2015
    Publication date: September 1, 2016
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Publication number: 20160243032
    Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 25, 2016
    Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M. Blanda, James N. Chang, Orest Olejnik
  • Publication number: 20160143988
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: January 29, 2016
    Publication date: May 26, 2016
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Patent number: 9327059
    Abstract: Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: May 3, 2016
    Assignee: Allergan, Inc.
    Inventors: Glenn T. Huang, Thierry Nivaggioli, Lon T. Spada, Hiroshi Sugimoto, Wendy M. Blanda, James N. Chang, Orest Olejnik
  • Patent number: 9265775
    Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: February 23, 2016
    Assignee: Allergan, Inc.
    Inventors: Robert T. Lyons, James N. Chang, John T. Trogden, Scott Whitcup
  • Publication number: 20160038396
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 11, 2016
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 9248191
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: February 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20160022581
    Abstract: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
    Type: Application
    Filed: October 6, 2015
    Publication date: January 28, 2016
    Inventors: Lon T. Spada, James N. Chang, Michelle H. Luu
  • Patent number: 9241918
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: January 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Publication number: 20160015717
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 21, 2016
    Inventors: CHIN-MING CHANG, JAMES N. CHANG, RHETT M. SCHIFFMAN, R. SCOTT JORDAN, JOAN-EN CHANG-LIN
  • Publication number: 20150343017
    Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.
    Type: Application
    Filed: August 10, 2015
    Publication date: December 3, 2015
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 9161970
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: October 20, 2015
    Assignee: Allergan, Inc.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 9155716
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Patent number: 9149428
    Abstract: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: October 6, 2015
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, James N. Chang, Michelle H. Luu
  • Patent number: 9101574
    Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: August 11, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone